Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 20/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4933522 | 0.84 | ESR1 (0.72) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3927438 | 0.83 | ESR1 (0.77) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3935834 | 0.82 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3932748 | 0.82 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3936474 | 0.81 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3933722 | 0.81 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3922605 | 0.78 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL8483557 | 0.76 | ESR1 (0.81) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3929820 | 0.75 | ESR1 (1.00) | ESR1ESR2HSP90AA1 | |
| SCHEMBL3922447 | 0.75 | ESR1 (1.00) | ESR1ESR2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-6884814-B2 | Phenyl benzisoxazoles as estrogenic agents | WYETH (US) | 2005-04-26 | — | — | US | claimed |
| US-20030207927-A1 | Phenyl benzisoxazoles as estrogenic agents | WYETH | 2003-11-06 | — | — | US | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20050159465-A1 | 3-(4-Hydroxy-2-methylphenyl)-1,2-benzisoxazol-6-ol; estrogen receptor modulators; ability to compete with 17 beta -estradiol for both Estrogen Receptor alpha and Estrogen Receptor beta; Estrogen Receptor Selective Agonist Antagonist activity; anticancer, antiinflammatory, anticholesterol | WYETH (US) | 2005-07-21 | — | — | US | disclosed |
| US-6884814-B2 | Phenyl benzisoxazoles as estrogenic agents | WYETH (US) | 2005-04-26 | — | — | US | disclosed |
| US-20030207927-A1 | Phenyl benzisoxazoles as estrogenic agents | WYETH | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207927-A1 | Phenyl benzisoxazoles as estrogenic agents | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885HSP90AA1 3050/4885 |
| US-20050159465-A1 | 3-(4-Hydroxy-2-methylphenyl)-1,2-benzisoxazol-6-ol; estrogen receptor modulators; ability to compete with 17 beta -estradiol for both Estrogen Receptor alpha and Estrogen Receptor beta; Estrogen Receptor Selective Agonist Antagonist activity; anticancer, antiinflammatory, anticholesterol | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885HSP90AA1 1899/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR1 4/4885ESR2 5/4885HSP90AA1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.